NASDAQ
Alzamend Neuro, Inc. (ALZN) has a free cash flow growth of -48.22% as of Friday, May 29, 2026. This represents a 935.57% decrease compared to its 12-month average of -4.66%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.